Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.

Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC).

Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.

2.

[Harmonization of data coding in post-transplant follow-up - "GVHD, complications and additional treatments": Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Cornillon J, Detrait M, Karam M, Le Bars L, Meziane Y, Pereira M, Richard-Leveille S, Marion S, Leroux S, Coiteux V, Raus N, Seris S, Guyotat D, Yakoub-Agha I, Laurent N.

Bull Cancer. 2019 Jan;106(1S):S71-S82. doi: 10.1016/j.bulcan.2018.10.003. Epub 2018 Nov 15. French.

PMID:
30448095
3.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE.

Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5.

PMID:
30195076
4.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group.

Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.

PMID:
29723417
5.

Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.

Garban F, Guyard A, Labussière H, Bulabois CE, Marchand T, Mounier C, Caillot D, Bay JO, Coiteux V, Schmidt-Tanguy A, Le Niger C, Robin C, Ladaique P, Lapusan S, Deconinck E, Rolland C, Foote AM, François A, Jacquot C, Tardivel R, Tiberghien P, Bosson JL; Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group.

JAMA Oncol. 2018 Apr 1;4(4):468-475. doi: 10.1001/jamaoncol.2017.5123.

6.

Successful treatment with fingolimod of graft-versus-host disease of the central nervous system.

Gauthier J, Vermersch P, Chauvet P, Varlet P, Coiteux V, Magro L, Yakoub-Agha I.

Blood Adv. 2018 Jan 2;2(1):10-13. doi: 10.1182/bloodadvances.2017011478. eCollection 2018 Jan 9.

7.

Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.

Cony-Makhoul P, Gardembas M, Coiteux V, Carpentier N, Pommier C, Violet I, Quittet P, Berger MG; TARGET-RMC Investigators.

Br J Haematol. 2018 Feb;180(3):356-364. doi: 10.1111/bjh.15042. Epub 2017 Dec 19.

PMID:
29265184
8.

Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease.

Hueso T, Gauthier J, Joncquel Chevalier-Curt M, Magro L, Coiteux V, Dulery R, Carpentier B, Labreuche J, Damaj G, Yakoub-Agha I, Seguy D.

Clin Gastroenterol Hepatol. 2018 Jun;16(6):908-917.e2. doi: 10.1016/j.cgh.2017.12.024. Epub 2017 Dec 16.

PMID:
29258901
9.

[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Simon N, Coiteux V, Bruno B, Taque S, Charbonnier A, Souchet L, Vincent L, Yakoub-Agha I, Chalandon Y.

Bull Cancer. 2017 Dec;104(12S):S99-S105. doi: 10.1016/j.bulcan.2017.07.010. Epub 2017 Nov 23. Review. French.

PMID:
29173979
10.

Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, Tabrizi R, Labussiere-Wallet H, Bernard M, Chantepie S, Bay JO, Thiebaut-Bertrand A, Thepot S, Contentin N, Fornecker LM, Maillard N, Risso K, Berceanu A, Blaise D, Peffault de La Tour R, Chien JW, Coiteux V, Socié G; ALLOZITHRO Study Investigators.

JAMA. 2017 Aug 8;318(6):557-566. doi: 10.1001/jama.2017.9938.

11.

Long-term follow up of invasive aspergillosis in allogeneic stem cell transplantation recipients and leukemia patients: Differences in risk factors and outcomes.

Bonnet S, Duléry R, Regany K, Bouketouche M, Magro L, Coiteux V, Alfandari S, Berthon C, Quesnel B, Yakoub-Agha I.

Curr Res Transl Med. 2017 Apr - Jun;65(2):77-81. doi: 10.1016/j.retram.2017.05.003. Epub 2017 Jul 5.

PMID:
28689016
12.

Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study.

Michallet M, Sobh M, Garban F, Bulabois CE, Yakoub-Agha I, Coiteux V, Dulery R, Rohrlich PS, Legrand F, Clement L, Praire A, Detrait M, Barraco F, Nicolini FE, Hequet O.

Leuk Lymphoma. 2018 Feb;59(2):372-380. doi: 10.1080/10428194.2017.1334120. Epub 2017 Jun 7.

PMID:
28587506
13.

Citrulline and Monocyte-Derived Macrophage Reactivity before Conditioning Predict Acute Graft-versus-Host Disease.

Hueso T, Coiteux V, Joncquel Chevalier Curt M, Labreuche J, Jouault T, Yakoub-Agha I, Seguy D.

Biol Blood Marrow Transplant. 2017 Jun;23(6):913-921. doi: 10.1016/j.bbmt.2017.03.005. Epub 2017 Mar 2.

14.

Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.

Duléry R, Nibourel O, Gauthier J, Elsermans V, Behal H, Coiteux V, Magro L, Renneville A, Marceau A, Boyer T, Quesnel B, Preudhomme C, Duhamel A, Yakoub-Agha I.

Bone Marrow Transplant. 2017 Apr;52(4):539-543. doi: 10.1038/bmt.2016.318. Epub 2017 Jan 9.

PMID:
28067876
15.

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group.

Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27.

16.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX; France Intergroupe des Leucémies Myéloïdes Chroniques.

Blood. 2017 Feb 16;129(7):846-854. doi: 10.1182/blood-2016-09-742205. Epub 2016 Dec 8.

17.

[Management of graft failure and erythroblastopenia in patients undergoing allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Cornillon J, Sicre de Fontbrune F, Chantepie S, Coiteux V, Gauthier J, Masouridi-Levrat S, Pochon C, Terriou L, Yakoub-Agha I, Dalle JH.

Bull Cancer. 2016 Nov;103(11S):S248-S254. doi: 10.1016/j.bulcan.2016.09.004. Epub 2016 Oct 31. Review. French.

PMID:
27810141
18.

Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.

Etienne G, Huguet F, Guerci-Bresler A, Nicolini FE, Maloisel F, Coiteux V, Dauriac C, Carpentier N, Bourdeix I, Tulliez M, Cony-Makhoul P.

Br J Haematol. 2016 Jul;174(1):71-80. doi: 10.1111/bjh.14022. Epub 2016 Apr 7.

PMID:
27060881
19.

Severe Adenovirus Pneumonia Followed by Bacterial Septicaemia: Relevance of Co-Infections in Allogeneic Hematopoietic Stem Cell Transplantation.

Engelmann I, Coiteux V, Heim A, Magro L, Dewilde A, Dulery R, Hober D, Yakoub-Agha I.

Infect Disord Drug Targets. 2016;16(1):69-76.

PMID:
27052333
20.

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.

Duployez N, Nibourel O, Ducourneau B, Grardel N, Boyer T, Bories C, Darre S, Coiteux V, Berthon C, Preudhomme C, Roche-Lestienne C.

Eur J Haematol. 2016 Oct;97(4):399-402. doi: 10.1111/ejh.12752. Epub 2016 Mar 26.

PMID:
26935241
21.

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

Rea D, Ame S, Charbonnier A, Coiteux V, Cony-Makhoul P, Escoffre-Barbe M, Etienne G, Gardembas M, Guerci-Bresler A, Legros L, Nicolini F, Tulliez M, Hermet E, Huguet F, Johnson-Ansah H, Lapusan S, Quittet P, Rousselot P, Mahon FX, Messas E.

Bull Cancer. 2016 Feb;103(2):180-9. doi: 10.1016/j.bulcan.2015.11.008. Epub 2016 Jan 11. French.

PMID:
26790711
22.

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.

Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX.

Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7.

PMID:
26687426
23.

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.

Dhédin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, Thomas X, Chevallier P, Nguyen S, Coiteux V, Bourhis JH, Hichri Y, Escoffre-Barbe M, Reman O, Graux C, Chalandon Y, Blaise D, Schanz U, Lhéritier V, Cahn JY, Dombret H, Ifrah N; GRAALL group.

Blood. 2015 Apr 16;125(16):2486-96; quiz 2586. doi: 10.1182/blood-2014-09-599894. Epub 2015 Jan 13.

24.

Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

Gomez E, Duléry R, Langlois C, Coiteux V, Terriou L, Magro L, Gauthier J, de Berranger E, Duhamel A, Yakoub-Agha I.

Bone Marrow Transplant. 2014 Dec;49(12):1492-7. doi: 10.1038/bmt.2014.193. Epub 2014 Sep 15.

PMID:
25222500
25.

[Impact of anti-HLA antibodies on outcomes of allogeneic stem cell transplantation: a report by the SFGM-TC].

Loiseau P, Dubois V, Bonafoux B, Bulabois CE, Coiteux V, Eliaou JF, Labaky M, Michallet M, Renac V, Delbos F, Kennel A, Detrait M, Devys A, Galambrun C, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):226-9. doi: 10.1016/j.patbio.2014.05.007. Epub 2014 Jun 25. French.

PMID:
24973858
26.

Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale.

Mauté C, Nibourel O, Réa D, Coiteux V, Grardel N, Preudhomme C, Cayuela JM; GBMHM.

Clin Biochem. 2014 Sep;47(13-14):1333-6. doi: 10.1016/j.clinbiochem.2014.05.067. Epub 2014 Jun 8.

PMID:
24915631
27.

[The impact of donor naive and memory T cell subsets on patient outcome following allogeneic stem cell transplantation: relationship between infused donor CD4+/CCR7+ T cell subsets and acute graft-versus-host disease].

Choufi B, Thiant S, Trauet J, Cliquennois M, Cherrel M, Boulanger F, Coiteux V, Magro L, Labalette M, Yakoub-Agha I.

Pathol Biol (Paris). 2014 Jun;62(3):123-8. doi: 10.1016/j.patbio.2014.02.013. Epub 2014 Jun 3. French.

PMID:
24906571
28.

Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.

Fouquet G, Guidez S, Herbaux C, Van de Wyngaert Z, Bonnet S, Beauvais D, Demarquette H, Adib S, Hivert B, Wemeau M, Berthon C, Terriou L, Coiteux V, Macro M, Decaux O, Facon T, Huglo D, Leleu X.

Clin Cancer Res. 2014 Jun 15;20(12):3254-60. doi: 10.1158/1078-0432.CCR-13-2910. Epub 2014 Apr 8.

29.

Antifungal stewardship: implementation in a French teaching hospital.

Alfandari S, Berthon C, Coiteux V.

Med Mal Infect. 2014 Apr;44(4):154-8. doi: 10.1016/j.medmal.2014.01.012. Epub 2014 Mar 4.

PMID:
24612504
30.

[Diagnosis and treatment of CMV and EBV Reactivation as well as Post-transplant Lymphoproliferative Disorders following Allogeneic Stem Cell Transplantation: An SFGM-TC report].

Bay JO, Peffault de Latour R, Bruno B, Coiteux V, Guillaume T, Hicheri Y, Paillard C, Suarez F, Turlure P, Alain S, Bulabois CE, Socié G, Bauters F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2013 Aug;61(4):152-4. doi: 10.1016/j.patbio.2013.07.003. Epub 2013 Sep 4. French.

PMID:
24011961
31.

Quantification of JAK2V617F mutation by next-generation sequencing technology.

Abdelhamid E, Figeac M, Renneville A, Quief S, Villenet C, Boyer T, Nibourel O, Coiteux V, Cassinat B, Lippert E, Helevaut N, Soua Z, Preudhomme C.

Am J Hematol. 2013 Jun;88(6):536-7. doi: 10.1002/ajh.23446. Epub 2013 May 13. No abstract available.

32.

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, Stamatoullas A, Choufi B, Delaunay J, Gourin MP, Cheze S, Ravoet C, Ferrant A, Escoffre-Barbe M, Aljassem L, Raffoux E, Itzykson R, Adès L, Dreyfus F, Fenaux P.

Leukemia. 2013 Jun;27(6):1283-90. doi: 10.1038/leu.2013.16. Epub 2013 Jan 16.

PMID:
23370672
33.

Fulminant cryptosporidiosis after near-drowning: a human Cryptosporidium parvum strain implicated in invasive gastrointestinal adenocarcinoma and cholangiocarcinoma in an experimental model.

Certad G, Benamrouz S, Guyot K, Mouray A, Chassat T, Flament N, Delhaes L, Coiteux V, Delaire B, Praet M, Cuvelier C, Gosset P, Dei-Cas E, Creusy C.

Appl Environ Microbiol. 2012 Mar;78(6):1746-51. doi: 10.1128/AEM.06457-11. Epub 2012 Jan 13.

34.

Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study.

Dulery R, Salleron J, Dewilde A, Rossignol J, Boyle EM, Gay J, de Berranger E, Coiteux V, Jouet JP, Duhamel A, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1080-9. doi: 10.1016/j.bbmt.2011.12.579. Epub 2011 Dec 30.

35.

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study.

Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, Iwaz J, Preudhomme C, Roche-Lestienne C, Facon T, Remontet L.

Blood. 2011 Oct 20;118(16):4331-7. doi: 10.1182/blood-2011-01-330332. Epub 2011 Aug 17.

36.

Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC.

Bay JO, Cabrespine A, Faucher C, Tabrizi R, Bordigoni P, Berceanu A, Coiteux V, Renaud M, Mialou V, Robin M, Kuentz M, Chevallier P, Dhédin N, Huynh A, Garban F, Witz F, Buzyn A, De Revel T, Galambrun C, Deconinck E, Contentin N, François S, Gratecos N, Blaise D, Michallet M; Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Biol Blood Marrow Transplant. 2012 Feb;18(2):250-6. doi: 10.1016/j.bbmt.2011.06.015. Epub 2011 Jul 13.

37.

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.

Roche-Lestienne C, Marceau A, Labis E, Nibourel O, Coiteux V, Guilhot J, Legros L, Nicolini F, Rousselot P, Gardembas M, Helevaut N, Frimat C, Mahon FX, Guilhot F, Preudhomme C; Fi-LMC group.

Leukemia. 2011 Oct;25(10):1661-4. doi: 10.1038/leu.2011.139. Epub 2011 Jun 3. No abstract available.

PMID:
21637286
38.

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.

Braun T, de Botton S, Taksin AL, Park S, Beyne-Rauzy O, Coiteux V, Sapena R, Lazareth A, Leroux G, Guenda K, Cassinat B, Fontenay M, Vey N, Guerci A, Dreyfus F, Bordessoule D, Stamatoullas A, Castaigne S, Terré C, Eclache V, Fenaux P, Adès L.

Leuk Res. 2011 Jul;35(7):863-7. doi: 10.1016/j.leukres.2011.02.008. Epub 2011 Mar 10.

PMID:
21396711
39.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).

N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095.

40.

Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD.

Thiant S, Labalette M, Trauet J, Coiteux V, de Berranger E, Dessaint JP, Yakoub-Agha I.

Bone Marrow Transplant. 2011 Oct;46(10):1374-81. doi: 10.1038/bmt.2010.300. Epub 2010 Dec 6.

PMID:
21132028
41.

Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging.

Mekinian A, Lions C, Leleu X, Duhamel A, Lamblin N, Coiteux V, De Groote P, Hatron PY, Facon T, Beregi JP, Hachulla E, Launay D; Lille Amyloidosis Study Group.

Am J Med. 2010 Sep;123(9):864-8. doi: 10.1016/j.amjmed.2010.03.022.

PMID:
20800158
42.

Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.

Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F.

Leuk Res. 2010 Nov;34(11):1430-6. doi: 10.1016/j.leukres.2010.05.030. Epub 2010 Jun 26.

PMID:
20580086
43.

Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse.

Thiant S, Yakoub-Agha I, Magro L, Trauet J, Coiteux V, Jouet JP, Dessaint JP, Labalette M.

Bone Marrow Transplant. 2010 Oct;45(10):1546-52. doi: 10.1038/bmt.2010.13. Epub 2010 Mar 1.

PMID:
20190846
44.

Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Garnier A, Robin M, Larosa F, Golmard JL, Le Gouill S, Coiteux V, Tabrizi R, Bulabois CE, Cacheux V, Kuentz M, Dreyfus B, Dreger P, Rio B, Moles-Moreau MP, Bilger K, Bay JO, Leblond V, Blaise D, Tournilhac O, Dhédin N.

Haematologica. 2010 Jun;95(6):950-5. doi: 10.3324/haematol.2009.017814. Epub 2010 Jan 15.

45.

SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia.

Poulain S, Ertault M, Leleu X, Coiteux V, Fernandes J, Stalnikiewicz L, Duthilleul P, Morel P.

Leuk Res. 2009 Sep;33(9):1204-7. doi: 10.1016/j.leukres.2009.03.031. Epub 2009 Apr 24.

PMID:
19394082
46.

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.

Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L, Jouet JP, Yakoub-Agha I.

Blood. 2009 Jul 16;114(3):719-22. doi: 10.1182/blood-2009-02-204750. Epub 2009 Mar 16.

47.

Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.

Yakoub-Agha I, Saule P, Magro L, Cracco P, Duhamel A, Coiteux V, Bruno B, Dufossé F, Jouet JP, Dessaint JP, Labalette M.

Biol Blood Marrow Transplant. 2009 Apr;15(4):496-504. doi: 10.1016/j.bbmt.2008.11.038. Epub 2009 Feb 12.

48.

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.

Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, Harousseau JL.

Haematologica. 2008 Dec;93(12):1908-11. doi: 10.3324/haematol.13285. Epub 2008 Sep 2.

49.

Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.

Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I.

Bone Marrow Transplant. 2008 Dec;42(11):757-60. doi: 10.1038/bmt.2008.252. Epub 2008 Sep 1.

PMID:
18762765
50.

L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.

Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thiéblemont C, Gaulard P, Marin B, Gachard N, Bordessoule D, Hermine O.

Ann Oncol. 2009 Jan;20(1):110-6. doi: 10.1093/annonc/mdn542. Epub 2008 Aug 13. Review.

PMID:
18701429

Supplemental Content

Loading ...
Support Center